partnerScore 60/100Watch
DeepMind spun out Isomorphic Labs to commercialize AlphaFold and AI-driven drug discovery, targeting 10x acceleration of drug development timeline (currently 10 years to candidate drug)
Demis Hassabis· Google DeepMind· AI· 2026-07-18· about DeepMind, Isomorphic Labs (subsidiary/spinout) (GOOGL)
“we've also spun out a new company isomorphic labs to specifically build on this work and other related work but specifically for drug discovery to accelerate drug discovery which we hope using computational ai methods can maybe be an order of magnitude quicker currently you know it takes an average of 10 years to go from identifying a target to a candidate drug”
Why it matters
DeepMind is commercializing AlphaFold-driven drug discovery through a dedicated spinout, signaling serious intent to disrupt the drug development timeline. This creates a new competitor/partner to traditional pharma/biotech.
Investment implication
Isomorphic Labs will be a key player in AI-driven drug discovery. Pharma/biotech companies may seek partnerships or acquisition. Competitors to Isomorphic (e.g., other AI drug discovery platforms like Exscientia, Atomwise) face new competitive pressure. Traditional CROs may need to integrate AI capabilities.